Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5079476 | 0.84 | KMT2A (0.51) | KMT2AALDH1A1KDM4ETSHRPOLB | |
| Trifluoroacetic Acid SCHEMBL3986645 | 0.83 | KDM4E (0.39) | PKMKMT2AALDH1A1KDM4EPOLB | |
| Trifluoromethanesulfonic Acid SCHEMBL16611581 | 0.83 | KDM4E (0.39) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| SCHEMBL5013 | 0.82 | KDM4E (0.52) | PKMKMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL477197 | 0.82 | KDM4E (0.52) | PKMKMT2AALDH1A1KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL311054 | 0.80 | KDM4E (0.50) | PKMKMT2AALDH1A1KDM4EPOLB | |
| Piperazine SCHEMBL28080505 | 0.80 | KDM4E (0.50) | PKMKMT2AALDH1A1KDM4ETSHR | |
| Potassium SCHEMBL30601760 | 0.80 | KDM4E (0.50) | PKMKMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL8742086 | 0.80 | KDM4E (0.50) | PKMKMT2AALDH1A1KDM4ETSHR | |
| Trifluoroacetic Acid SCHEMBL6956793 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KDM4ETSHRPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4074711-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| CN-114901658-A | Nitrogen-containing heterocyclic ring autotaxin inhibitor, and composition and application thereof | 四川海思科制药有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021115375-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | 四川海思科制药有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-7208499-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050256144-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-20050215582-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2005056543-A2 | PROCESS FOR USE IN THE PREPARATION OF OXIRANES FROM ALKENES, AND CATALYSTS FOR USE THEREIN | AVECIA PHARMACEUTICALS LIMITED (GB) | 2005-06-23 | — | — | WO | disclosed |
| EP-1539758-A1 | SUBSTITUTED PYRROLOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016610-A1 | SUBSTITUTED PYRROLOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
| CN-1072666-C | (Azetidin-1-ylalkyl) lactams as tachykinin antagonists | PFIZER RES AND DEV CO N V S A (IE) | 2001-10-10 | — | — | CN | disclosed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | disclosed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1154699-A | (Azetidin-1-ylalkyl) lactams as tachykinin antagonists | PFIZER LTD (IE) | 1997-07-16 | — | — | CN | disclosed |
| US-5561140-A | IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | ABBOTT LABORATORIES (US) | 1996-10-01 | — | — | US | disclosed |
| US-5530119-A | IMMUNOSUPPRESSANTS | ABBOTT LABORATORIES (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| EP-0690713-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994021254-A1 | SUBSTITUTED ALICYCLIC AMINE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256144-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, DPYD | PKM 2590/4885KMT2A 2578/4885ALDH1A1 166/4885 |
| US-20230069174-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | ENPP2, NMT2, NMT1 | PKM 4619/4885KMT2A 2849/4885ALDH1A1 4631/4885 |
| US-20050215582-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | PKM 87/4885KMT2A 2562/4885ALDH1A1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.